2021 Revenues ($USD) : $9,479,000,000
2021 R&D spend : not available
2021 Number of Employees : 30,000
Fiscal Year End : 9/30/2021
Key People : Tom Polen, chair, CEO and president; Christopher DelOrefice, EVP and CFO; Alberto Mas, EVP and president, Medical segment; Simon D. Campion, EVP and president, Interventional segment; Alexandre Conroy, EVP, Integrated Supply Chain; Tony Ezell, president North America and chief marketing officer; Jerry Flasz, EVP, Global Services and chief information officer; Roland Goette, EVP and president, Europe, Middle East and Africa (EMEA); Dave Hickey, EVP and president, Life Sciences segment; Sam Khichi, EVP, corporate development and public affairs, regulatory affairs and general counsel; Betty Larson, EVP and chief human resources officer; James Lim, EVP and president, Greater Asia; Elizabeth McCombs, EVP and CTO; Christopher R. Reidy, EVP and chief administrative officer; David Shan, EVP and chief quality officer; William R. Sigmund II, EVP and chief medical officer; Ami Simunovich, EVP and chief regulatory officer.

About the company: Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, Becton, Dickinson and Co. (BD) is comprised of three segments: medical, interventional and life sciences. The company’s first sale was a glass syringe — a product the company continues to sell today. BD employs nearly 70,000 people across 50 countries, led by CEO Thomas Polen, who took up the leadership position in early 2020. The Franklin Lakes, New Jersey-based company’s medical segment includes diabetes care, medication delivery solutions, medication management solutions and pharmaceutical systems, although BD announced earlier this year that it intends to spin off its diabetes arm as an independent, publicly-traded company. The medical segment includes syringes and hypodermic needles, both of which have come to the fore amid the COVID-19 pandemic as the company has provided several hundred million injection devices for the United States’ federal vaccination campaign, having amassed more than 2 billion orders and expanded its manufacturing capacity. The segment also includes BD’s infusion systems, many of which including the Alaris platform were brought into the company through its $12.2 billion acquisition of CareFusion in 2015. Earlier this year, BD acquired Velano Vascular as part of an effort to change the standard of care in blood collection through its “one-stick stay” initiative. The company also develops diagnostics and surgical products, among several other offerings across its interventional and life sciences arms. –SW